Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma
- Determine the antitumor immune response in patients with unresectable stage III or IV
melanoma treated with vaccine comprising multiple synthetic melanoma peptides,
sargramostim (GM-CSF), and Montanide ISA-51.
OUTLINE: Patients receive vaccine comprising multiple synthetic melanoma peptides,
sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, 15, 29, 36, and 43. Patients
undergo removal of the lymph node draining the vaccination site on day 22 to assess immune
PROJECTED ACCRUAL: A maximum of 29 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Craig L. Slingluff, MD
University of Virginia
United States: Federal Government
|Cancer Center at the University of Virginia||Charlottesville, Virginia 22908|